WaRMINNCT05794399
Anticoagulation in Post MI LV Thrombus Trial in Nepal
StatusRecruiting
PhasePhase 4
Primary completion (estimated)
At risk: Primary completion moved at least 2 years 8 months later.
See at-risk trials from Shahid Gangalal National Heart Centre
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion dates pushed to Dec 2028 Show 4 more changesShow less
- Eligibility criteria expanded, about 8 words
- Secondary endpoints: details revised at 2 of 2 entries
- Study description revised
- Publications: details revised at 14 of 15 entries
- Notable Primary completion date: Mar 2025 to Mar 2026
- Study completion date: Apr 2025 to Apr 2026
- Notable Primary completion date: Mar 2024 to Mar 2025
- Study completion date: Apr 2024 to Apr 2025
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Jun 2023 to Jun 19, 2023
- Notable Start date: Apr 2023 to Jun 2023v3
- Minor Study description expanded, about 6 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
LV thrombus resolution
Timeframe: 3 months
Secondary (2)
Major bleeding events
Embolic events
Arms and interventions
RivaroxabanExperimental
In this arm, the patients with post-myocardial infarction and left ventricular thrombus will be treated with Rivaroxaban 20mg or 15mg as indicated.
WarfarinActive comparator
In this arm, the patients with post-myocardial infarction and left ventricular thrombus will be treated with warfarin with a dose adjusted with the International Normalised ratio range of 2.0 to 3.0.
Drugs: Rivaroxaban, Warfarin
Sites
1 site in 1 country
- Nepal Health Research CouncilKathmandu, Bagmati, Nepal